Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Palsonify (paltusotine) is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
• Both oral octreotide capsules (OOCs) and paltusotine maintained biochemical control in acromegaly patients who were previously controlled with injectable somatostatin receptor ligands (SRLs).
• Long-term maintenance of biochemical control was confirmed for OOCs, while paltusotine demonstrated short-term maintenance with no available long-term data.
• No significant differences in effectiveness were reported among different population types or subgroups.
• There is no safety information available in the reviewed studies.
• The findings apply to patients with acromegaly previously controlled with SRLs; no additional population types or subgroup information is available in the reviewed studies.